Physician profile
Daniel Joseph Brouder
NPI 1659313963
$5,238.20
in general payments reported to CMS, 2019-2025
33 companies · $1,180 in 2025
The $1,180 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $421 · 2021: $374 · 2022: $798 · 2023: $761 · 2024: $939 · 2025: $1,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,843 · Education: $37.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,842.61 |
| Education | $37.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,557.20 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $408.83 | 2019-2025 | Veltassa |
| Glaxosmithkline, LLC. | $324.91 | 2022-2025 | Benlysta, Jesduvroq, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.64 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $296.23 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $287.51 | 2020-2025 | Tavneos, Parsabiv, Krystexxa |
| Fresenius USA Marketing, INC. | $196.83 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $166.31 | 2021-2025 | |
| Ardelyx, INC. | $153.95 | 2023-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $143.58 | 2022-2025 | Lupkynis |
| Horizon Therapeutics Plc | $132.55 | 2019-2021 | |
| Lemaitre Vascular, INC. | $128.27 | 2024 | Artegraft Vascular Graft |
| Mallinckrodt Hospital Products INC. | $122.18 | 2020-2025 | Terlivaz |
| Calliditas Therapeutics US INC. | $119.34 | 2022-2025 | Tarpeyo |
| Daiichi Sankyo INC. | $112.12 | 2019-2024 | Injectafer |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $111.33 | 2019-2025 | Rayaldee |
| Travere Therapeutics, INC. | $109.22 | 2023-2025 | |
| Akebia Therapeutics INC | $103.42 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $82.96 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $58.98 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $40.79 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $36.49 | 2019-2022 | |
| Lilly USA, LLC | $34.84 | 2025 | Jardiance |
| Scpharmaceuticals INC. | $32.23 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.46 | 2020 | |
| Octapharma USA, INC. | $24.96 | 2019 | |
| Ani Pharmaceuticals, INC. | $21.53 | 2025 | Purified Cortrophin Gel |
| Pharmacosmos Therapeutics INC. | $18.05 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $17.00 | 2020 | |
| Apellis Pharmaceuticals, INC. | $15.92 | 2025 | |
| Shire North American Group INC | $14.98 | 2019 | |
| Amarin Pharma, INC. | $14.08 | 2020 | |
| Xeris Pharmaceuticals, INC. | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Brouder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.